Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles.

Leitner DR, Lichtenegger S, Temel P, Zingl FG, Ratzberger D, Roier S, Schild-Prüfert K, Feichter S, Reidl J, Schild S.

Front Microbiol. 2015 Aug 11;6:823. doi: 10.3389/fmicb.2015.00823. eCollection 2015.

2.

Killed oral cholera vaccines: history, development and implementation challenges.

Lopez AL, Gonzales ML, Aldaba JG, Nair GB.

Ther Adv Vaccines. 2014 Sep;2(5):123-36. doi: 10.1177/2051013614537819. Review.

3.

Critical analysis of compositions and protective efficacies of oral killed cholera vaccines.

Kabir S.

Clin Vaccine Immunol. 2014 Sep;21(9):1195-205. doi: 10.1128/CVI.00378-14. Epub 2014 Jul 23. Review.

4.

Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.

Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, Kampman K.

Drug Alcohol Depend. 2014 Jul 1;140:42-7. doi: 10.1016/j.drugalcdep.2014.04.003. Epub 2014 Apr 16.

5.

Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.

Leitner DR, Feichter S, Schild-Prüfert K, Rechberger GN, Reidl J, Schild S.

Infect Immun. 2013 Jul;81(7):2379-93. doi: 10.1128/IAI.01382-12. Epub 2013 Apr 29.

6.

Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks.

Hamorsky KT, Kouokam JC, Bennett LJ, Baldauf KJ, Kajiura H, Fujiyama K, Matoba N.

PLoS Negl Trop Dis. 2013;7(3):e2046. doi: 10.1371/journal.pntd.0002046. Epub 2013 Mar 7.

7.

Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.

Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR.

Arch Gen Psychiatry. 2009 Oct;66(10):1116-23. doi: 10.1001/archgenpsychiatry.2009.128.

8.

Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis.

Bitsaktsis C, Rawool DB, Li Y, Kurkure NV, Iglesias B, Gosselin EJ.

J Immunol. 2009 Apr 15;182(8):4899-909. doi: 10.4049/jimmunol.0803242.

9.

Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera.

Schild S, Nelson EJ, Bishop AL, Camilli A.

Infect Immun. 2009 Jan;77(1):472-84. doi: 10.1128/IAI.01139-08. Epub 2008 Nov 10.

10.

Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice.

Schild S, Nelson EJ, Camilli A.

Infect Immun. 2008 Oct;76(10):4554-63. doi: 10.1128/IAI.00532-08. Epub 2008 Aug 4.

12.
14.

Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine.

Sanchez AE, Aquino G, Ostoa-Saloma P, Laclette JP, Rocha-Zavaleta L.

Clin Diagn Lab Immunol. 2004 Jul;11(4):711-9.

15.
16.

T- and B-cell immune responses of patients who had undergone colectomies to oral administration of Salmonella enterica serovar Typhi Ty21a vaccine.

Kilhamn J, Lundin SB, Brevinge H, Svennerholm AM, Jertborn M.

Clin Diagn Lab Immunol. 2003 May;10(3):426-30.

17.

Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.

Johansson EL, Wassén L, Holmgren J, Jertborn M, Rudin A.

Infect Immun. 2001 Dec;69(12):7481-6.

18.

Human gastric B cell responses can be induced by intestinal immunisation.

Quiding-Järbrink M, Lönroth H, Ahlstedt I, Holmgren J, Svennerholm AM.

Gut. 2001 Oct;49(4):512-8.

19.

Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans.

Jertborn M, Nordström I, Kilander A, Czerkinsky C, Holmgren J.

Infect Immun. 2001 Jun;69(6):4125-8.

20.

Induction and distribution of intestinal immune responses after administration of recombinant cholera toxin B subunit in the ileal pouches of colectomized patients.

Kilhamn J, Brevinge H, Quiding-Järbrink M, Svennerholm AM, Jertborn M.

Infect Immun. 2001 May;69(5):3466-71. Erratum in: Infect Immun 2001 Oct;69(10):6564.

Items per page

Supplemental Content

Write to the Help Desk